Vanda Pharmaceuticals Inc.

VNDA

US9216591084

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:09:14 2024-06-07 pm EDT			5-day change	1st Jan Change
6.17 ^USD	-1.59%		+19.57%	+44.79%

Jun. 06	Sector Update: Health Care Stocks Higher in Late Afternoon Trading	MT
Jun. 06	Sector Update: Health Care Stocks Advance Thursday Afternoon	MT

Vanda Pharmaceuticals Inc. Provides Sales Guidance for the Year 2021

July 28, 2021 at 04:01 pm EDT

Vanda Pharmaceuticals Inc. provided sales guidance for the year 2021. For the year, it expects total revenues of $270 to $300 million.

Latest news about Vanda Pharmaceuticals Inc.

Sector Update: Health Care Stocks Higher in Late Afternoon Trading	Jun. 06	MT
Sector Update: Health Care Stocks Advance Thursday Afternoon	Jun. 06	MT
Sector Update: Health Care	Jun. 06	MT
Vanda Pharmaceuticals' Shares Rally After Company Receives $466 Million Buyout Offer From Cycle Pharma	Jun. 06	MT
Cycle Pharmaceuticals Offers to Buy Vanda Pharmaceuticals for $466 Million	Jun. 06	MT
Top Premarket Gainers	Jun. 06	MT
Cycle Pharmaceuticals Limited made a proposal to acquire Vanda Pharmaceuticals Inc. for approximately $490 million.	Jun. 05	CI
Vanda Pharmaceuticals to Commercialize Treatment of Multiple Sclerosis in the US	May. 31	MT
Global markets live: UBS, Tesla, Nvidia, Apple, Micron...	May. 27
Vanda Pharmaceuticals rejects Future Pak's revised takeover offer	May. 24	RE
Vanda Pharmaceuticals rejects Future Pak's deal	May. 24	RE
Future Pak, Ltd. cancelled the acquisition of Vanda Pharmaceuticals Inc. from The Vanguard Group, Inc., Renaissance Technologies LLC, BlackRock, Inc., Butler Hall Capital LLC, Shareholder Capital LLC and others.	May. 23	CI
Vanda Pharmaceuticals Says Second Phase 3 Study of Tradipitant in Motion Sickness Yields 'Positive' Results	May. 15	MT
Vanda Pharmaceuticals Inc. Reports Positive Results from A Second Phase III Study of Tradipitant in Motion Sickness	May. 15	CI
Transcript : Vanda Pharmaceuticals Inc., Q1 2024 Earnings Call, May 08, 2024	May. 08
Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q1 Revenue $47.5M	May. 08	MT
Vanda Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Sector Update: Health Care Stocks Advance in Late Afternoon Trading	May. 07	MT
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading	May. 07	MT
Sector Update: Health Care	May. 07	MT
Vanda Pharmaceuticals Shares Rise After Future Pak Adds $260 Million Potential Payments to Cash Offer	May. 07	MT
Future Pak sweetens buyout offer for Vanda Pharmaceuticals	May. 07	RE
Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer	Apr. 25	RE
Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court	Apr. 22	MT
U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents	Apr. 22	RE

Chart Vanda Pharmaceuticals Inc.

Duration

Period

More charts

Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Companyâs commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Sector

Biotechnology & Medical Research

Calendar

2024-07-30 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Vanda Pharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.27 USD

Average target price

5.21 USD

Spread / Average Target

-16.91%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VANDA PHARMACEUTICALS INC.	+44.79%	365M
VERTEX PHARMACEUTICALS INCORPORATED	+19.10%	125B
REGENERON PHARMACEUTICALS, INC.	+14.55%	108B
BIONTECH SE	-4.90%	24.57B
ARGENX SE	+3.23%	22.82B
GENMAB A/S	-10.44%	18.19B
WUXI APPTEC CO., LTD.	-41.74%	16.54B
BEIGENE, LTD.	-13.31%	16.5B
NEUROCRINE BIOSCIENCES, INC.	+2.87%	13.39B
SAREPTA THERAPEUTICS, INC.	+28.74%	11.1B

Bio Therapeutic Drugs